The Clayco Foundation is committed to supporting meaningful research to find treatments and a cure for Retinal vasculopathy with cerebral leukoencephalopathy (RVCL), a rare genetic disease.
We have made great strides and progress over this past year. Illumination 2022 was an incredible record-breaking gala for The Clayco Foundation in October, where we raised $1.1 million to help support the search for a cure for RVCL and to help pave the way for cures for all genetic orphan diseases.
Now Penn Medicine’s RVCL Research Center, led by Jonathan Miner, MD, PhD, has been recognized as a national leader performing cutting-edge research with the goal of developing precise and personalized therapies for patients with retinal vasculopathy with cerebral leukoencephalopathy.
Dr. Miner relocated from St. Louis to Philadelphia in 2021 and is considered one of the foremost experts in the field of RVCL, seeing patients, overseeing clinical trials, and staying current with all relevant research. Miner is motivated to lead these efforts as he knows that this is a solvable problem because it’s a disease caused by a single gene mutation, and that the disease is going to be eventually treatable.
The team at Penn Medicine partners with patients, physicians, and scientists from across Penn and around the world and is pushing forward faster than ever. This recent article in the Philadelphia Inquirer details some of the work done by the team and how Miner established the RVCL Research Center at Penn to help families who have the genetic mutations that cause the disease.